BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang Z, Zhang J, Lu Y, Xu Q, Tang B, Wang Q, Zhang W, Chen S, Lu L, Chen X. Aspartate aminotransferase-lymphocyte ratio index and systemic immune-inflammation index predict overall survival in HBV-related hepatocellular carcinoma patients after transcatheter arterial chemoembolization. Oncotarget 2015;6:43090-8. [PMID: 26506519 DOI: 10.18632/oncotarget.5719] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 6.1] [Reference Citation Analysis]
Number Citing Articles
1 Sun WW, Hu JA, Niu WQ, Gao BL, Xu ZH. Significance of NLDA, the commixed index of inflammation, immune responses, hemostasis, and nutrition, for predicting metastatic non-small cell lung cancer prognosis and metastases. Oncotarget 2017;8:81978-93. [PMID: 29137238 DOI: 10.18632/oncotarget.18184] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
2 Suh KJ, Kim SH, Kim YJ, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Lee JS. Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody. Cancer Immunol Immunother 2018;67:459-70. [PMID: 29204702 DOI: 10.1007/s00262-017-2092-x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 67] [Article Influence: 12.6] [Reference Citation Analysis]
3 Wang B, Huang Y, Lin T. Prognostic impact of elevated pre-treatment systemic immune-inflammation index (SII) in hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore) 2020;99:e18571. [PMID: 31895801 DOI: 10.1097/MD.0000000000018571] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
4 Cho YY, Yu SJ, Yoo JJ, Lee M, Lee DH, Cho Y, Yoon KW, Cho EJ, Lee JH, Kim YJ, Yoon JH. The Model to Estimate Survival in Ambulatory Hepatocellular Carcinoma Patients Aids in the Decision for TACE Retreatment. J Clin Gastroenterol 2020;54:370-7. [PMID: 30439763 DOI: 10.1097/MCG.0000000000001148] [Reference Citation Analysis]
5 Quiros-Roldan E, Properzi M, Amadasi S, Raffetti E, Ferraresi A, Biasi L, Focà E, Castelli F. Prognostic role of inflammatory biomarkers in HIV-infected patients with a first diagnosis of hepatocellular carcinoma: A single-center study. J Med Virol 2019;91:241-8. [PMID: 30216474 DOI: 10.1002/jmv.25317] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Qi X, Li J, Deng H, Li H, Su C, Guo X. Neutrophil-to-lymphocyte ratio for the prognostic assessment of hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. Oncotarget 2016;7:45283-301. [PMID: 27304193 DOI: 10.18632/oncotarget.9942] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 9.7] [Reference Citation Analysis]
7 Casadei Gardini A, Scarpi E, Orlandi E, Tassinari D, Leo S, Bernardini I, Gelsomino F, Tamberi S, Ruscelli S, Vespignani R, Ronconi S, Frassineti GL, Amadori D, Passardi A. Prognostic role of aspartate aminotransferase-lymphocyte ratio index in patients with metastatic colorectal cancer: results from the randomized ITACa trial. Onco Targets Ther 2018;11:5261-8. [PMID: 30214231 DOI: 10.2147/OTT.S166614] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
8 Casadei Gardini A, Foschi FG, Conti F, Petracci E, Vukotic R, Marisi G, Buonfiglioli F, Vitale G, Ravaioli F, Gitto S, Verucchi G, Lenzi M, Bolondi L, Mazzella G, Brillanti S, Andreone P. Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals. Digestive and Liver Disease 2019;51:681-8. [DOI: 10.1016/j.dld.2018.09.016] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
9 Wang K, Diao F, Ye Z, Zhang X, Zhai E, Ren H, Li T, Wu H, He Y, Cai S, Chen J. Prognostic value of systemic immune-inflammation index in patients with gastric cancer. Chin J Cancer 2017;36:75. [PMID: 28899420 DOI: 10.1186/s40880-017-0243-2] [Cited by in Crossref: 51] [Cited by in F6Publishing: 56] [Article Influence: 10.2] [Reference Citation Analysis]
10 Wu Y, Tu C, Shao C. The value of preoperative systemic immune-inflammation index in predicting vascular invasion of hepatocellular carcinoma: a meta-analysis. Braz J Med Biol Res 2021;54:e10273. [PMID: 33656054 DOI: 10.1590/1414-431X202010273] [Reference Citation Analysis]
11 Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Michel M, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto Dos Santos D, Pitton MB, Düber C, Kloeckner R. Immunonutritive Scoring for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Evaluation of the CALLY Index. Cancers (Basel) 2021;13:5018. [PMID: 34638502 DOI: 10.3390/cancers13195018] [Reference Citation Analysis]
12 Conroy G, Salleron J, Belle A, Bensenane M, Nani A, Ayav A, Peiffert D, Lopez A, Baumann C, Barraud H, Bronowicki JP. The prognostic value of inflammation-based scores in advanced hepatocellular carcinoma patients prior to treatment with sorafenib. Oncotarget 2017;8:95853-64. [PMID: 29221172 DOI: 10.18632/oncotarget.21401] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
13 Wang L, Wang C, Wang J, Huang X, Cheng Y. A novel systemic immune-inflammation index predicts survival and quality of life of patients after curative resection for esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2017;143:2077-86. [PMID: 28601935 DOI: 10.1007/s00432-017-2451-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 39] [Article Influence: 5.8] [Reference Citation Analysis]
14 Xie QK, Chen P, Hu WM, Sun P, He WZ, Jiang C, Kong PF, Liu SS, Chen HT, Yang YZ, Wang D, Yang L, Xia LP. The systemic immune-inflammation index is an independent predictor of survival for metastatic colorectal cancer and its association with the lymphocytic response to the tumor. J Transl Med 2018;16:273. [PMID: 30286769 DOI: 10.1186/s12967-018-1638-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
15 Zhong JH, Huang DH, Chen ZY. Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis. Oncotarget. 2017;8:75381-75388. [PMID: 29088873 DOI: 10.18632/oncotarget.18856] [Cited by in Crossref: 69] [Cited by in F6Publishing: 77] [Article Influence: 13.8] [Reference Citation Analysis]
16 Dai W, Jia B, Yang J, Zhou S, Liu P, He X, Qin Y, Gui L, Zhang C, Han X, Sun Y, Shi Y. Development of new prognostic model based on pretreatment βLRI and LLRI for stage IE/IIE upper aerodigestive tract ENKTL, nasal type. Oncotarget 2017;8:34787-95. [PMID: 28410236 DOI: 10.18632/oncotarget.16720] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
17 Jin J, Xu H, Wu R, Gao N, Wu N, Li S, Niu J. Identification of key genes and pathways associated with different immune statuses of hepatitis B virus infection. J Cell Mol Med 2019;23:7474-89. [PMID: 31565863 DOI: 10.1111/jcmm.14616] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
18 Huang L, Liu S, Lei Y, Wang K, Xu M, Chen Y, Liu B, Chen Y, Fu Q, Zhang P, Qin K, Cai Y, Fu S, Ge S, Yuan X. Systemic immune-inflammation index, thymidine phosphorylase and survival of localized gastric cancer patients after curative resection. Oncotarget 2016;7:44185-93. [PMID: 27283904 DOI: 10.18632/oncotarget.9923] [Cited by in Crossref: 38] [Cited by in F6Publishing: 44] [Article Influence: 9.5] [Reference Citation Analysis]
19 Liu KJ, Lv YX, Niu YM, Bu Y. Prognostic value of γ-glutamyl transpeptidase to albumin ratio combined with aspartate aminotransferase to lymphocyte ratio in patients with hepatocellular carcinoma after hepatectomy.Medicine (Baltimore). 2020;99:e23339. [PMID: 33235099 DOI: 10.1097/MD.0000000000023339] [Reference Citation Analysis]
20 Ji F, Fu S, Guo Z, Pang H, Chen D, Wang X, Ju W, Wang D, He X, Hua Y, Peng B. Prognostic significance of preoperative aspartate aminotransferase to neutrophil ratio index in patients with hepatocellular carcinoma after hepatic resection. Oncotarget. 2016;7:72276-72289. [PMID: 27472390 DOI: 10.18632/oncotarget.10848] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
21 Geng Y, Shao Y, Zhu D, Zheng X, Zhou Q, Zhou W, Ni X, Wu C, Jiang J. Systemic Immune-Inflammation Index Predicts Prognosis of Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score-matched Analysis. Sci Rep 2016;6:39482. [PMID: 28000729 DOI: 10.1038/srep39482] [Cited by in Crossref: 67] [Cited by in F6Publishing: 74] [Article Influence: 11.2] [Reference Citation Analysis]
22 Mouchli M, Reddy S, Gerrard M, Boardman L, Rubio M. Usefulness of neutrophil-to-lymphocyte ratio (NLR) as a prognostic predictor after treatment of hepatocellular carcinoma." Review article. Ann Hepatol 2021;22:100249. [PMID: 32896610 DOI: 10.1016/j.aohep.2020.08.067] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
23 Lin K, Huang Q, Wang L, Zeng J, Ding Z, Liu H, Fu J, Guo P, Chen Z, Zeng Y, Zhou W, Liu J. Pre- and Postoperative Models for Prediction of Recurrence in Non-B, Non-C Hepatocellular Carcinoma. Front Oncol 2021;11:612588. [PMID: 33680963 DOI: 10.3389/fonc.2021.612588] [Reference Citation Analysis]
24 Young S, Cam I, Gencturk M, Rubin N, D'souza D, Flanagan S, Golzarian J, Sanghvi T. Inflammatory Scores: Comparison and Utility in HCC Patients Undergoing Transarterial Chemoembolization in a North American Cohort. J Hepatocell Carcinoma 2021;8:1513-24. [PMID: 34881208 DOI: 10.2147/JHC.S335183] [Reference Citation Analysis]
25 He C, Peng W, Li C, Wen TF. Postoperative aspartate aminotransferase to lymphocyte ratio index change is an independent predictor of survival in patients with small hepatocellular carcinoma. Medicine (Baltimore) 2017;96:e8540. [PMID: 29137062 DOI: 10.1097/MD.0000000000008540] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
26 Li QX, Shi DJ, Zhang LX, Wang DM, Zhao J, Wang T, Deng XN, Fan XY. Association of body mass and systemic immune-inflammation indices with endocrine therapy resistance in luminal breast cancers. J Int Med Res 2019;47:1936-47. [PMID: 30843447 DOI: 10.1177/0300060519831570] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
27 Yang R, Chang Q, Meng X, Gao N, Wang W. Prognostic value of Systemic immune-inflammation index in cancer: A meta-analysis. J Cancer. 2018;9:3295-3302. [PMID: 30271489 DOI: 10.7150/jca.25691] [Cited by in Crossref: 60] [Cited by in F6Publishing: 68] [Article Influence: 15.0] [Reference Citation Analysis]
28 Zhao Y, Si G, Zhu F, Hui J, Cai S, Huang C, Cheng S, Fathy AH, Xiang Y, Li J. Prognostic role of platelet to lymphocyte ratio in hepatocellular carcinoma: a systematic review and meta-analysis. Oncotarget 2017;8:22854-62. [PMID: 28206965 DOI: 10.18632/oncotarget.15281] [Cited by in Crossref: 23] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
29 Hong YM, Yoon KT, Cho M. Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma. BMC Cancer 2021;21:569. [PMID: 34006248 DOI: 10.1186/s12885-021-08124-9] [Reference Citation Analysis]
30 Xin Y, Yang Y, Liu N, Chen Y, Wang Y, Zhang X, Li X, Zhou X. Prognostic significance of systemic immune-inflammation index-based nomogram for early stage hepatocellular carcinoma after radiofrequency ablation. J Gastrointest Oncol 2021;12:735-50. [PMID: 34012662 DOI: 10.21037/jgo-20-342] [Reference Citation Analysis]
31 Chen JH, Zhai ET, Yuan YJ, Wu KM, Xu JB, Peng JJ, Chen CQ, He YL, Cai SR. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol 2017; 23(34): 6261-6272 [PMID: 28974892 DOI: 10.3748/wjg.v23.i34.6261] [Cited by in CrossRef: 96] [Cited by in F6Publishing: 95] [Article Influence: 19.2] [Reference Citation Analysis]
32 Hu W, Yu J, Huang Y, Hu F, Zhang X, Wang Y. Lymphocyte-Related Inflammation and Immune-Based Scores Predict Prognosis of Chordoma Patients After Radical Resection. Transl Oncol. 2018;11:444-449. [PMID: 29477108 DOI: 10.1016/j.tranon.2018.01.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
33 Yang Z, Zhuang L, Lu Y, Xu Q, Tang B, Chen X. Naturally occurring basal core promoter A1762T/G1764A dual mutations increase the risk of HBV-related hepatocellular carcinoma: a meta-analysis. Oncotarget 2016;7:12525-36. [PMID: 26848866 DOI: 10.18632/oncotarget.7123] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
34 Passardi A, Scarpi E, Cavanna L, Dall'Agata M, Tassinari D, Leo S, Bernardini I, Gelsomino F, Tamberi S, Brandes AA, Tenti E, Vespignani R, Frassineti GL, Amadori D, De Giorgi U. Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer. Oncotarget 2016;7:33210-9. [PMID: 27120807 DOI: 10.18632/oncotarget.8901] [Cited by in Crossref: 77] [Cited by in F6Publishing: 78] [Article Influence: 15.4] [Reference Citation Analysis]
35 Li GJ, Ji JJ, Yang F, Xu HW, Bai Y. Preoperative lymphocyte-to-monocyte ratio predicts survival in primary hepatitis B virus-positive hepatocellular carcinoma after curative resection. Onco Targets Ther 2017;10:1181-9. [PMID: 28260933 DOI: 10.2147/OTT.S110411] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
36 Zhao LY, Yang DD, Ma XK, Liu MM, Wu DH, Zhang XP, Ruan DY, Lin JX, Wen JY, Chen J, Lin Q, Dong M, Qi JJ, Hu PS, Zeng ZL, Chen ZH, Wu XY. The Prognostic Value of aspartate aminotransferase to lymphocyte ratio and systemic immune-inflammation index for Overall Survival of Hepatocellular Carcinoma Patients Treated with palliative Treatments. J Cancer 2019;10:2299-311. [PMID: 31258733 DOI: 10.7150/jca.30663] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
37 Pinato DJ, Howell J, Ramaswami R, Sharma R. Review article: delivering precision oncology in intermediate-stage liver cancer. Aliment Pharmacol Ther 2017;45:1514-23. [DOI: 10.1111/apt.14066] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
38 Zhang Y, Lin S, Yang X, Wang R, Luo L. Prognostic value of pretreatment systemic immune-inflammation index in patients with gastrointestinal cancers. J Cell Physiol 2019;234:5555-63. [PMID: 30353545 DOI: 10.1002/jcp.27373] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
39 Yang J, Xu H, Guo X, Zhang J, Ye X, Yang Y, Ma X. Pretreatment Inflammatory Indexes as Prognostic Predictors for Survival in Colorectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy. Sci Rep 2018;8:3044. [PMID: 29445100 DOI: 10.1038/s41598-018-21093-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
40 Wang Y, Sun K, Shen J, Li B, Kuang M, Cao Q, Peng S. Novel Prognostic Nomograms Based on Inflammation-Related Markers for Patients with Hepatocellular Carcinoma Underwent Hepatectomy. Cancer Res Treat 2019;51:1464-78. [PMID: 30913869 DOI: 10.4143/crt.2018.657] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
41 Shi F, Zhang L, Li S, Lin CJ, Shen LJ, Li CF, Jie M, Li ZW, Wu PH. Chemolipiodolization with or without embolization in transcatheter arterial chemoembolization combined with radiofrequency ablation for hepatocellular carcinoma-propensity score matching analysis. Oncotarget 2016;7:31311-21. [PMID: 27121318 DOI: 10.18632/oncotarget.8897] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
42 Qiu H, Liu C, Huang M, Shen S, Wang W. Prognostic Value of Combined CA19-9 with Aspartate Aminotransferase to Lymphocyte Ratio in Patients with Intrahepatic Cholangiocarcinoma After Hepatectomy. Cancer Manag Res 2021;13:5969-80. [PMID: 34377017 DOI: 10.2147/CMAR.S320380] [Reference Citation Analysis]
43 Gao XH, Tian L, Wu J, Ma XL, Zhang CY, Zhou Y, Sun YF, Hu B, Qiu SJ, Zhou J, Fan J, Guo W, Yang XR. Circulating CD14+ HLA-DR-/low myeloid-derived suppressor cells predicted early recurrence of hepatocellular carcinoma after surgery. Hepatol Res. 2017;47:1061-1071. [PMID: 27764536 DOI: 10.1111/hepr.12831] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
44 Peng X, Huang Y, Zhang M, Chen Y, Zhang L, He A, Luo R, Kim Y. Prognostic and Clinical Significance of Aspartate Aminotransferase-to-Lymphocyte Ratio Index in Individuals with Liver Cancer: A Meta-Analysis. Disease Markers 2022;2022:1-9. [DOI: 10.1155/2022/3533714] [Reference Citation Analysis]
45 Jiang W, Chen Y, Huang J, Xi D, Chen J, Shao Y, Xu G, Ying W, Wei J, Chen J, Ning Z, Gu W, Pei H. Systemic immune-inflammation index predicts the clinical outcome in patients with nasopharyngeal carcinoma: a propensity score-matched analysis. Oncotarget 2017;8:66075-86. [PMID: 29029493 DOI: 10.18632/oncotarget.19796] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]